Stockscreener 앱 받기
10.38
3.08%
0.31
시장 영업 전:
10.41
0.03
+0.29%
4 D Molecular Therapeutics Inc 주식(FDMT)의 최신 뉴스
4D Molecular Therapeutics Inc (FDMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
4D Molecular Therapeutics Inc (FDMT) Income Statement - TradingKey
4D Molecular Therapeutics Inc (FDMT) Balance Sheet - TradingKey
4D Molecular Therapeutics Inc (FDMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
4D Molecular Therapeutics Inc (FDMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
4D Molecular Therapeutics Inc (FDMT) Cash Flow - TradingKey
FDMT|4D Molecular Therapeutics Inc|Price:10.200| - TradingKey
4D Molecular Therapeutics Inc - TradingKey
4D Molecular Therapeutics Inc (FDMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
FDMT|4D Molecular Therapeutics Inc|Price:10.070|Chg%:-0.310 - TradingKey
4D Molecular releases phase 2 data for wet AMD asset 4D-150 - MSN
4D Molecular's one-shot eye therapy delivers two-year win - MSN
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM) - The Globe and Mail
4D Molecular Therapeutics (FDMT) Reports Positive Phase 2 Results for AMD Treatment - GuruFocus
4D Molecular Therapeutics reports positive 2-year Phase 2b PRISM data for 4D-150 in wet AMD - Bitget
symbol__ Stock Quote Price and Forecast - CNN
4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity (FDMT) - Seeking Alpha
4D Molecular Therapeutics Posts Strong 4D-150 Trial Results - TipRanks
Why Is 4D Molecular Therapeutics Stock Gaining Monday?4D Molecular Therapeutics (NASDAQ:FDMT) - Benzinga
4D Molecular Therapeutics Reports Positive 2-Year Phase 2b Results for 4D-150 in Wet AMD, Shows Reduced Treatment Burden and Strong Safety Profile 5678 – Minichart - Minichart
4D Molecular Therapeutics (Nasdaq: FDMT) posts positive 2-year wet AMD data - Stock Titan
4D Molecular Therapeutics (FDMT) TD Cowen 46th Annual Health Care Conference summary - Quartr
4D Molecular Therapeutics (FDMT) Morgan Stanley 23rd Annual Global Healthcare Conference summary - Quartr
4D Molecular Therapeutics Announces Positive Two-Year PRISM Phase 2b Data for 4D-150 in Wet AMD - Quiver Quantitative
A single 4D-150 dose cut wet AMD treatment burden 78% - Stock Titan
4DMT Announces New Employment Inducement Grants - GlobeNewswire
4DMT Grants 37,900 Restricted Stock Units to Six New Employees - Stock Titan
Price to book forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
4d Molecular Therapeutics CEO David Kirn sells $737k in stock By Investing.com - Investing.com South Africa
4d Molecular Therapeutics CEO David Kirn sells $737k in stock - Investing.com Nigeria
Form 4 4D Molecular Therapeutics Inc For: 14 July - Investing.com India
Form 4 4D Molecular Therapeutics Inc For: 14 July By Investing.com - Investing.com Canada
4D Molecular Therapeutics (NASDAQ: FDMT) insider executes 58K-share 10b5-1 sale - Stock Titan
Form 144 4D Molecular Therapeutics For: 10 July By Investing.com - Investing.com South Africa
FDMT (FDMT) insider plans Form 144 Class A share sale and lists prior trades - Stock Titan
Form 144 4D Molecular Therapeutics For: 9 July By Investing.com - Investing.com Canada
David Kirn sells Class A shares for FDMT (FDMT) in June 2026 - Stock Titan
FDMT4D Molecular Therapeutics Inc Revenue Breakdown - Finviz
Price to earnings forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
FDMT Gains 2.44% as Stock Holds Above Key Support at $12.35High Volume Stocks - dars.gov.et
FDMT (NASDAQ: FDMT) CLO sells 6,566 shares, exercises options under 10b5-1 plan - Stock Titan
Morgan Stanley Keeps Their Hold Rating on 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Form 144 4D Molecular Therapeutics For: 30 June By Investing.com - Investing.com Canada
FDMT (NASDAQ: FDMT) insider 10b5-1 sale of 9,810 shares for $117,720 - Stock Titan
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists - The Manila Times
4DMT to present 2-year PRISM trial follow-up at retina meeting - Stock Titan
H.C. Wainwright reiterates Buy on 4D Molecular stock on trial progress By Investing.com - Investing.com Canada
Morgan Stanley Maintains 4D Molecular Therapeutics(FDMT.US) With Hold Rating - Moomoo
4D Molecular Therapeutics Shares Rise After New Credit Facility - Moomoo
4D Molecular Therapeutics secures $200M credit facility - Investing.com
4D Molecular (FDMT) Completes Enrollment for Phase 3 Clinical Tr - GuruFocus
4D Molecular Therapeutics Completes Enrollment for 4Front-2 Global Phase 3 Clinical Trial of 4D-150 in Wet Amd - marketscreener.com
4D Molecular Therapeutics Secures Strategic Credit Facility for Up to $200 Million from Hercules Capital - marketscreener.com
4D Molecular Therapeutics secures $200M credit facility By Investing.com - Investing.com Australia
4D Molecular Therapeutics Secures $200 Million Loan Facility - TipRanks
4D Molecular Therapeutics Secures Up to $200 Million Term Loan Facility From Hercules Capital - TradingView
4D Molecular Therapeutics (FDMT) signs up to $200M secured loan with Hercules - Stock Titan
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital - The Manila Times
4DMT finishes Phase 3 enrollment for wet AMD gene therapy trial - Stock Titan
1.97%
0.83%
자본화:
|
볼륨(24시간):